Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Figure out How to Advance Space in Your Pre-assembled Home for Upgraded Usefulness - 2Vote in favor of the juice that you love for its medical advantages!
- 3Comet C/2025 K1 (ATLAS) breaks apart in incredible telescope photos
- 4Mount Everest Climbers 'Poisoned' by Guides Prompting Mass Helicopter Rescues in $20 Million Insurance Fraud Scheme, Police Say
- 5Going on a bad date is a drag. Worse? Ending up as a cautionary tale on TikTok.
- 2024 Manual for Light Extravagance Room Feel: What's Moving
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- Instructions to Safeguard Your Speculations In the midst of Changing Disc Rates
- Activists: Venezuela released just nine prisoners despite promise
- Skeleton of famed musketeer possibly found in Dutch church
- Cyprus: War-related tourism concerns and climate change efforts
- Top notch DSLR Cameras for Photography Devotees
- Vote In favor of Your Favored Shades
- Careful Connections: Building Association and Trust
